Associated Papers
Molecular insights for the tumor suppressor role of SPOP in prostate cancer.
Yan P et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2026
Neo-Cysteine Molecular Glues for Targeting Mutated SMAD4 Protein.
Kumari P et al.
Angewandte Chemie (international Ed. in English), 2026
Cancer-associated SPOP mutations enlarge nuclear size and facilitate nuclear envelope rupture upon farnesyltransferase inhibitor treatment.
Wang Z et al.
The Journal of Clinical Investigation, 2025
SPOP-dependent destabilization of SYT12 in a GSK-3β-dependent manner in papillary thyroid cancer cells.
Zhou S et al.
Clinical and Experimental Medicine, 2025
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population.
Arun AS et al.
The Pharmacogenomics Journal, 2025
Decoding the functional impact of the cancer genome through protein-protein interactions.
Fu H et al.
Nature Reviews. Cancer, 2025
Updates on SPOP Gene Mutations in Prostate Cancer and Computational Insights From TCGA cBioPortal Database.
Zakari S et al.
Scientifica, 2025
ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance.
Lee CJ et al.
Cell Death & Disease, 2024
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
Deficiency in SPOP-mediated ubiquitination and degradation of TIAM1 promotes gastric cancer progression.
Liu F et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease, 2024
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
Geng C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers.
Cavalcante L et al.
Jco Precision Oncology, 2023
SPOP targets the immune transcription factor IRF1 for proteasomal degradation.
Schwartz I et al.
Elife, 2023
Mass spectrometry-based targeted proteomics for analysis of protein mutations.
Lin TT et al.
Mass Spectrometry Reviews, 2023
CHD1, a multifaceted epigenetic remodeler in prostate cancer.
Li H et al.
Frontiers in Oncology, 2023
SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF.
Feng K et al.
Cell & Bioscience, 2022
Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
White JA et al.
Cancer Research Communications, 2022
ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
Fan Y et al.
Cell Death and Differentiation, 2022
SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer.
Shi Q et al.
Cell Death and Differentiation, 2022
GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer.
Burleson M et al.
Molecular Cancer Research : Mcr, 2022
Combined DNA repair defects in testicular metastasis from prostate cancer sensitize to immune checkpoint blockade.
Vlachostergios PJ
Current Urology, 2021
Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer.
Mizuno K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Luo Z et al.
Neoplasia (new York, N.y.), 2021
SPOP mutation induces DNA methylation via stabilizing GLP/G9a.
Zhang J et al.
Nature Communications, 2021
SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions.
Jiang Q et al.
Molecular Cancer, 2021
Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.
Jin X et al.
Nucleic Acids Research, 2021
Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Shi L et al.
Cancer Research, 2021
ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication.
Wang D et al.
Science Advances, 2021
SPOP-PTEN-SUFU axis promotes progression of clear cell renal cell carcinoma via activating SHH and WNT pathway.
Han B et al.
Cell Death Discovery, 2021
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
Bernasocchi T et al.
Nature Communications, 2021
A disease-relevant mutation of SPOP highlights functional significance of ATM-mediated DNA damage response.
Xiao M et al.
Signal Transduction and Targeted Therapy, 2021
The SPOP-ITCH Signaling Axis Protects Against Prostate Cancer Metastasis.
Ma J et al.
Frontiers in Oncology, 2021
The Roles of SPOP in DNA Damage Response and DNA Replication.
Maekawa M et al.
International Journal of Molecular Sciences, 2020
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M et al.
Ebiomedicine, 2020
SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
Watanabe R et al.
Molecular Biology of the Cell, 2020
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.
Dong X et al.
Communications Biology, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Shi Q et al.
Molecular Cancer, 2019
The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Yan Y et al.
Embo Molecular Medicine, 2019
Molecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative Prostate Cancer.
Bhatia V et al.
Trends in Molecular Medicine, 2019